Innate Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	28.09	66.4	70.61	84.23	103.76
Short-Term Investments	6.22	14.37	21.85	17.26	16.08
Cash & Short-Term Investments	34.31	80.77	92.46	101.49	119.84
Cash Growth	-57.52%	-12.64%	-8.90%	-15.31%	-20.97%
Accounts Receivable	12.4	0.65	15.23	3.08	0.85
Other Receivables	-	0.99	31.26	27.94	12.63
Receivables	12.4	1.64	46.49	31.02	13.47
Prepaid Expenses	-	2.82	5.69	4.67	2.58
Other Current Assets	-	0.51	3.37	2.65	2.36
Total Current Assets	46.71	85.74	148.01	139.83	138.26
Property, Plant & Equipment	4.36	5.13	6.32	8.54	10.17
Long-Term Investments	10.46	10.28	9.8	35.12	39.88
Other Intangible Assets	-	-	0.42	1.56	44.19
Long-Term Accounts Receivable	0.25	-	-	-	-
Long-Term Deferred Tax Assets	-	-	-	-	5.03
Other Long-Term Assets	0.95	9.9	10.64	14.25	29.97
Total Assets	62.72	111.06	175.19	199.3	267.5
Accounts Payable	15.04	7.92	8.56	13.66	14.73
Current Portion of Long-Term Debt	8.8	8.44	8.45	1.28	29.94
Current Portion of Leases	-	0.27	0.49	0.82	0.8
Current Income Taxes Payable	-	6.96	7.02	5.98	7.46
Current Unearned Revenue	9.33	8.06	13.51	16.78	19.92
Other Current Liabilities	3.48	1.33	1.61	2.82	7.03
Total Current Liabilities	36.65	32.98	39.64	41.34	79.89
Long-Term Debt	13.77	22.18	30.61	38.93	11.49
Long-Term Leases	-	0.1	0.35	1.22	2.01
Long-Term Unearned Revenue	31.75	43.95	49.65	60.91	58.41
Pension & Post-Retirement Benefits	1.92	2.73	2.44	2.55	2.98
Long-Term Deferred Tax Liabilities	-	-	-	-	5.03
Other Long-Term Liabilities	0.33	0.27	0.6	0.2	0.25
Total Liabilities	84.42	102.23	123.29	145.14	160.06
Common Stock	4.69	4.19	4.04	4.01	3.98
Additional Paid-In Capital	408.03	390.98	384.26	379.64	375.22
Retained Earnings	-435.54	-386.36	-336.89	-330.32	-272.21
Comprehensive Income & Other	1.12	0.03	0.5	0.82	0.46
Shareholders' Equity	-21.7	8.83	51.9	54.15	107.44
Total Liabilities & Equity	62.72	111.06	175.19	199.3	267.5
Total Debt	22.57	31	39.89	42.25	44.25
Net Cash (Debt)	11.74	49.78	52.56	59.23	75.59
Net Cash Growth	-76.42%	-5.30%	-11.26%	-21.63%	-42.98%
Net Cash Per Share	0.13	0.61	0.65	0.74	0.95
Filing Date Shares Outstanding	92.25	92.16	80.86	80.19	79.54
Total Common Shares Outstanding	92.25	83.83	80.86	80.19	79.54
Working Capital	10.06	52.76	108.38	98.49	58.37
Book Value Per Share	-0.24	0.11	0.64	0.68	1.35
Tangible Book Value	-21.7	8.83	51.49	52.6	63.25
Tangible Book Value Per Share	-0.24	0.11	0.64	0.66	0.80

Source: S&P Global Market Intelligence. Standard template. Financial Sources.